EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Dupilumab and Psoriasis Risk in Patients With Atopic Dermatitis: A Multicenter Cohort Study

Brandon R Block iD, Jaanvi Mehta iD, Alice Tang iD, Benjamin Ungar iD, Nicholas Gulati iD

Experimental Dermatology · 2026

DOI: 10.1111/exd.70378 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Experimental Dermatology, 2026. Verfasst von Brandon R Block und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Psoriasis, Antibodies, Monoclonal. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab treatment for atopic dermatitis (AD) has been linked to incident psoriasis, possibly reflecting a T helper 2 (Th2) to Th17 immune shift, but its risk relative to alternative contemporary AD‐directed therapies is unclear. To address this question, we performed parallel retrospective cohort studies using the TriNetX Global Collaborative Network and Epic Cosmos. In TriNetX, propensity score‐matched dupilumab cohorts were compared with topical corticosteroids (TCS), alternative anti‐Th2 biologics (nemolizumab, lebrikizumab, tralokinumab) or Janus kinase (JAK) inhibitors (abrocitinib, upadacitinib), with two‐year incident psoriasis assessed via Cox hazard ratios (HRs). Cosmos' larger patient pool permitted an exploratory analysis with agent‐level comparisons, evaluating relative risk (RR) of incident psoriasis within a 17‐month span. Dupilumab was not associated with increased two‐year psoriasis risk versus TCS (HR 0.91, 95% CI 0.77–1.08), alternative anti‐Th2 biologics (HR 1.03, 0.49–2.14) or JAK inhibitors (HR 0.86, 0.48–1.51). The data from Cosmos were in line with these findings, with equivalent or lower incidence with dupilumab relative to alternative agents. These data do not support a dupilumab‐specific risk of incident psoriasis and may instead reflect diagnostic ambiguity and/or genetic susceptibility to systemic immune shifts; nevertheless, these proposed explanations require confirmation in prospective studies incorporating clinical, histopathologic and genetic data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedPsoriasisAntibodies, MonoclonalHumansFemaleRetrospective StudiesMaleAdultAdrenal Cortex HormonesJanus Kinase InhibitorsMiddle AgedCohort StudiesHeterocyclic Compounds, 3-RingPyrimidinesProportional Hazards ModelsSulfonamides

Stichwörter der Autor:innen

Janus kinase inhibitorT helper 2TriNetXatopic dermatitisbiologiccosmosdupilumabpsoriasistopical corticosteroid

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabAdrenal Cortex HormonesJanus Kinase InhibitorsabrocitinibAntibodies, MonoclonalnemolizumablebrikizumabHeterocyclic Compounds, 3-RingPyrimidines

Autor:innen und Institutionen

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Brandon R Block, Jaanvi Mehta, Alice Tang, Benjamin Ungar, Nicholas Gulati

Zitieren

APA

Block, B. R., Mehta, J., Tang, A., Ungar, B., & Gulati, N. (2026). Dupilumab and Psoriasis Risk in Patients With Atopic Dermatitis: A Multicenter Cohort Study. Experimental Dermatology. https://doi.org/10.1111/exd.70378

Vancouver

Block BR, Mehta J, Tang A, Ungar B, Gulati N. Dupilumab and Psoriasis Risk in Patients With Atopic Dermatitis: A Multicenter Cohort Study. Experimental Dermatology. 2026. doi:10.1111/exd.70378

BibTeX
@article{Block2026,
  author = {Block, Brandon R and Mehta, Jaanvi and Tang, Alice and Ungar, Benjamin and Gulati, Nicholas},
  title = {Dupilumab and Psoriasis Risk in Patients With Atopic Dermatitis: A Multicenter Cohort Study},
  journal = {Experimental Dermatology},
  year = {2026},
  doi = {10.1111/exd.70378}
}
Kostenlos starten →